Studies employing a combination of Crizitonib together with PF-05212384 or gedatolisib were performed to additionally inhibit the phosphatidyl inositol-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway in the tumor cells. This evidence concerns the gene MTOR and neoplasm.